When to Start Treatment -- Research

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

Earlier Treatment of HIV Could Help HIV-Positive People Avoid Long-Term Complications, Recommendations Say (August 5, 2008)
A panel of the International AIDS Society-USA has issued new recommendations for when physicians should initiate HAART.
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
HIV Meds May Help Prevent Illness and Death at CD4 Counts Above 350, Study Finds (April 14, 2008)
In aidsmap.com
Starting HIV Meds Early Is Better for Your Health Than Waiting, Study Says (April 14, 2008)
In aidsmap.com
CROI: Could earlier ART Reduce Risk of Death from Non-AIDS Related Illnesses in People With HIV? (February 6, 2008)
From aidsmap.com
New HIV Treatment Guidelines in Europe Recommend Starting Meds at 350 (October 25, 2007)
In aidsmap.com
Possible Benefit to Starting Treatment at High CD4 Count, Massive Study Finds (August 24, 2007)
The study of more than 17,000 people who had never taken HIV meds found that, even among those with a CD4 count well over 350, the higher the count, the less likely they were to develop an AIDS-related illness or die.
From aidsmap.com
First-Line Therapy: What Should You Take? (July 2, 2007)
Discusses Choosing Among Drug Classes , Efavirenz-Based Combinations , Ritonavir-Boosted PI-Based Regimens and Considering NRTIs.
From The Body PRO
Three Months of Meds in Early Infection May Slow Down HIV in the Long Run (June 26, 2007)
From aidsmap.com
Voices Grow Louder in Support of Earlier HAART Initiation (January 12, 2007)
From aidsmap.com
Large Study Backs Starting HIV Treatment When CD4 Count Is Above 350 (January 9, 2007)
From aidsmap.com
Veterans Medical Affairs Researchers to Request NIH Funding for Study Examining Best Time to Start Antiretroviral Treatment (January 8, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
CD4 Percentage May Be Useful for Deciding Whether to Start HIV Treatment (January 5, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Strategic Use of Antiretroviral Therapy: What to Use and When? (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Two Studies Examine Potential Benefit of Beginning ART During Acute Infection (September 1, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Optimal Timing of HAART Initiation Does Not Differ With Regimens That Include Efavirenz or Ritonavir-Boosted Protease Inhibitors (August 15, 2006)
In XVI International AIDS Conference
To Start or Not to Start? CD4 Percentage May Provide Guidance (August 29, 2005)
Among people with a CD4 count above 350, HIV disease progression is found to be 3.6 times more likely for those with a CD4 percentage below 17%.
From aidsmap.com
Tangle of Interests and Disclosure Omissions Cracks Authors' Case for Early, Aggressive Treatment (January 2005)
AIDS advocate Mike Barr expresses concern over the influence of drug company money on HIV clinical practice -- and over some journals' lax disclosure policies.
In TAGline, from Treatment Action Group
HIV JournalView: When to Start Antiretroviral Therapy? (December 2004)
Several articles in Clinical Infectious Diseases debate starting treatment earlier in infants and adults than current guidelines recommend.
From The Body PRO
Articles Debate Starting HIV Therapy at CD4 Count Over 350 (November 23, 2004)
From aidsmap.com
Injection Drug Users Should Start HAART Earlier, Study Suggests (September 8, 2004)
From aidsmap.com
Study Supports Early Start to NNRTI-Based HAART (July 1, 2004)
A small London study finds that early treatment causes viral load to drop to levels similar to long-term HIV nonprogressors.
In Journal of AIDS
Update on the Treatment of Acute and Early HIV Infection (May 2004)
Details of a talk by Dr. Martin Markowitz of the Aaron Diamond AIDS Research Center and Dr. Bruce Walker of Harvard Medical School; includes a discussion of drug resistance transmission.
In The PRN Notebook
Adherence, not Baseline CD4 Cell Count, Linked to CD4 Cell Gain on HAART (February 25, 2004)
New support for those who feel treatment should be delayed until a patient's CD4 cell count falls near 200.
From aidsmap.com
Little Benefit Seen for Treatment During Acute Infection (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Gastrointestinal Side Effects Lead One in Eight to Change HAART Regimen in First Year of Treatment (November 27, 2003)
More than half of new HAART patients were also found to switch or stop their initial regimens within the first year, often without consulting their doctors.
From aidsmap.com
Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 x 109 Cells/L (November 18, 2003)
In Annals of Internal Medicine
NNRTI-Based HAART Associated With Quicker CD4 Cell Gains Than PI-Based Therapy (November 13, 2003)
Most of the patients in this large but non-randomized Canadian study were taking nevirapine (Viramune).
In The XIII International AIDS Conference, from aidsmap.com
Induction/Maintenance Approach Revived -- But Will Patients Stick With It? (October 28, 2003)
From aidsmap.com
Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration
Interim Analysis of Failure of Tenofovir/Abacavir/3TC Regimen (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Efavirenz or Nevirapine Regimens Are More Potent Than Trizivir for Initial Therapy (September 15, 2003)
A 100-patient Spanish study confirms the findings of ACTG 5095.
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Emergence of Resistance-Associated Mutations Over 96 Weeks in Patients Initiating ABC/3TC + d4T, EFV or APV/r (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Kaletra "Monotherapy" Safe and Efficacious for Treatment-Naive Patients (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
No Major Renal Problems With Tenofovir Were Identified in the Naive Population Evaluated in the GS 903 Study (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Recent Advances in the Clinical Management of the Antiretroviral-Naive Patient (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Treatment Regimens Containing Efavirenz, Nevirapine or Kaletra Are the Most Potent Options for Patients Starting Therapy (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Trizivir Plus Efavirenz Potent for Naive Patients With Low CD4 Counts and High Viral Loads (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Abacavir Not Inferior to AZT in Treatment-Naive Patients (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
When to Begin Highly Active Antiretroviral Therapy? Evidence Supporting Initiation of Therapy at CD4+ Lymphocyte Counts <350 Cells (September 12, 2003)
In Clinical Infectious Diseases
A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens Versus a 3-Drug Regimen, in Advanced Human Immunodeficiency Virus Disease (September 1, 2003)
Patients with advanced HIV are found to benefit the most from HAART regimens containing efavirenz (Sustiva), as opposed to regimens containing nelfinavir (Viracept) or no NNRTI at all.
In Journal of Infectious Diseases
Viread, Epivir and Ziagen Combination -- Failure in Naive Patients With a Once-Daily Regimen (September/October 2003)
Daniel S. Berger, M.D., chief investigator in study ESS30009, examines what went wrong.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Wait Six Months After HIV Treatment Begins to Determine Prognosis, Study Says (August 29, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration
Abacavir/3TC/Tenofovir Combination Fails in Treatment-Naive Patients (July 14, 2003)
Analysis by Benjamin Young, M.D., Ph.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Abacavir/3TC/Tenofovir Combination Failure in Treatment-Naive Patients (July 14, 2003)
Analysis by Timothy Wilkin, M.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
ACTG 5095: Efavirenz-Based Regimens Outperform Triple Nucleoside Combination (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Addition of Abacavir Does Not Appreciably Enhance the Antiviral Potency of a Standard Triple-Therapy Regimen (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Another Look at Induction Maintenance Therapy (July 14, 2003)
48-week data on Trizivir and efavirenz in treatment-naive patients.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
CD4 Count at Treatment Initiation Has Decreased Over the Years (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Comparison of Once-Daily FTC Vs. Twice-Daily Abacavir in a Regimen for Drug-Naive Patients (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Efavirenz-Based HAART Outperforms a Triple Nucleoside Regimen in Clinical Practice (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
For Potency Tenofovir Equals d4T but Tenofovir Beats d4T With Less Frequent and Common Side Effects (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Forty-Eight Week Data From FTC-d4T Comparison in Treatment-Naive Patients (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
FTC Potent Within a HAART Regimen in Treatment-Naive HIV-Infected Patients With High Viral Loads (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
More Results Reported on Study 903: Tenofovir + 3TC + Efavirenz Vs. d4T + 3TC + Efavirenz (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Nevirapine- Versus Efavirenz-Containing Three-Drug Regimens (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Trizivir Often Successful in Treatment-Naive Patients; Resistance Testing Key for Failures (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Abandon Trizivir When It's Working Well? A Rebuttal (July 2003)
Emily J. Erbelding, M.D., says: Don't fix what ain't broke.
In Hopkins HIV Report
Early HAART Extends Life, Costs Less, Study Says -- Despite Cardiovascular Risks (June 11, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
The Buzz: Anatomy of a Study -- Trizivir vs. Sustiva (May/June 2003)
A closer look at ACTG 5095, which examined the use of Trizivir and efavirenz in several first-line treatment regimens.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
CROI 2003: When, and With What, to Initiate Antiretroviral Treatment (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Is HAART for Primary/Early HIV Infection Associated With Improved Outcomes After Treatment Discontinuation? (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Antiretroviral Therapy: When to Start and What to Start With (September 2002)
A review of the latest research presented at Barcelona.
In Hopkins HIV Report
Earlier Initiation of HAART Better Preserves Functional Immune Competence Even in Persons Who Achieve "Normal" CD4+ T-Cell Counts (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO
When to Start ARV Therapy: Where Are We Now? (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
When to Start Antiretroviral Therapy? (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Prognosis of HIV-1 Infected Drug-Naive Patients Starting Potent Antiretroviral Therapy: Multi-Cohort Analysis of 12,040 Patients (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Where Epidemiology Meets Biology: Primary HIV Infection and Sexual Transmission (December 2001)
In The PRN Notebook
HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load (November 28, 2001)
In Journal of the American Medical Association
Initiating Antiretroviral Therapy During HIV Infection (November 28, 2001)
An editorial.
In Journal of the American Medical Association
New Finding May Help Doctors Prevent HIV Drug Resistance (November 22, 2001)
From U.S. National Institute of Allergy and Infectious Diseases
Initiation of Highly Active Antiretroviral Therapy (HAART) at CD4 Level 350: Assessment of Disease Progression, and Drug Failure, Toxicity, and Resistance (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
When to Start Antiretroviral Therapy; Considerations in Choosing an Initial Regimen; When to Change Regimens; Options for Managing Failure (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Optimizing Available Antiretroviral Therapies (February 8, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
CD4 + Lymphocyte Level Is Better than HIV-1 Plasma Viral Load in Determining When to Initiate HAART (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Low Lymph Node Viral Load Despite High Viremia in Seroconverters Supports Early HAART Intervention (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Long-Term Survival After Initiation of Antiretroviral Therapy (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Cohort Studies Suggesting Immediate HAART Confers No Extra Benefit Compared with Deferred HAART in HIV-Infected Persons CD4 >200 cells/mm³ (March 2000)
In TAGline, from Treatment Action Group
A Call for More Cautious Antiretroviral Treatment (February 18, 2000)
From AIDS Treatment News

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.